Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6396758 | 0.91 | L3MBTL1 (0.41) | L3MBTL1 | |
| SCHEMBL6393899 | 0.89 | MCL1 (0.40) | L3MBTL1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6396542 | 0.82 | CDK4 (0.40) | NPC1RAB9AMAPTALDH1A1LMNA | |
| SCHEMBL6398150 | 0.79 | EPHX1 (0.42) | LMNASMN1; SMN2 | |
| SCHEMBL6401232 | 0.79 | CDK4 (0.49) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6396585 | 0.78 | KMT2A (0.41) | KMT2A | |
| SCHEMBL6401223 | 0.78 | CDK4 (0.48) | MEN1NPC1RAB9AKMT2ALMNA | |
| SCHEMBL6402252 | 0.77 | ELANE (0.43) | MAPTAPLNRSMN1; SMN2 | |
| SCHEMBL6397950 | 0.77 | ELANE (0.40) | — | |
| SCHEMBL6395342 | 0.76 | LMNA (0.46) | ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | claimed |
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | MKI67, CCNC, PCNA | L3MBTL1 3588/4885MEN1 482/4885NPC1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.